PT1140200E - Medicamentos anticancerosos a base de antraquinona - Google Patents

Medicamentos anticancerosos a base de antraquinona

Info

Publication number
PT1140200E
PT1140200E PT99959561T PT99959561T PT1140200E PT 1140200 E PT1140200 E PT 1140200E PT 99959561 T PT99959561 T PT 99959561T PT 99959561 T PT99959561 T PT 99959561T PT 1140200 E PT1140200 E PT 1140200E
Authority
PT
Portugal
Prior art keywords
anticanceral
antraquinone
medicines
formula
tertiary
Prior art date
Application number
PT99959561T
Other languages
English (en)
Inventor
Laurence Hylton Patterson
Gerard Andrew Potter
Paul Teesdale-Spittle
Zennia Paniwynk
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montfort filed Critical Univ Montfort
Publication of PT1140200E publication Critical patent/PT1140200E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
PT99959561T 1998-12-24 1999-12-09 Medicamentos anticancerosos a base de antraquinona PT1140200E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828670.1A GB9828670D0 (en) 1998-12-24 1998-12-24 Anthraquinone anticancer drugs

Publications (1)

Publication Number Publication Date
PT1140200E true PT1140200E (pt) 2003-03-31

Family

ID=10845050

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99959561T PT1140200E (pt) 1998-12-24 1999-12-09 Medicamentos anticancerosos a base de antraquinona

Country Status (12)

Country Link
US (1) US6465522B1 (pt)
EP (1) EP1140200B1 (pt)
JP (1) JP2002533418A (pt)
AT (1) ATE227588T1 (pt)
AU (1) AU759549B2 (pt)
CA (1) CA2356399A1 (pt)
DE (1) DE69903974T2 (pt)
DK (1) DK1140200T3 (pt)
ES (1) ES2188273T3 (pt)
GB (1) GB9828670D0 (pt)
PT (1) PT1140200E (pt)
WO (1) WO2000038734A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800615B2 (en) 2002-04-15 2004-10-05 Board Of Trustees Of Michigan State University Antihelminthic anthraquinones and method of use thereof
US20040236414A1 (en) * 2003-05-23 2004-11-25 Brar Balbir S. Devices and methods for treatment of stenotic regions
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
WO2007083114A1 (en) * 2006-01-17 2007-07-26 Somanta, Incorporated Alchemix for the treatment of cancer
US8420861B2 (en) * 2007-10-16 2013-04-16 D. Richard Ishmael Anti-tumor compounds derived from 1,4,5,8-tetrachloroanthraquinone
CA2848726C (en) 2011-08-19 2019-09-10 Emory University Bax agonist, compositions, and methods related thereto
AU2015256266B2 (en) 2014-05-05 2019-01-17 Emory University BH4 antagonists and methods related thereto
CN108395379A (zh) * 2018-03-30 2018-08-14 南京医科大学康达学院 一种米托蒽醌的半合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES472508A1 (es) * 1977-08-15 1979-10-16 American Cyanamid Co Procedimiento para la obtencion de derivados de antraquinona
CS231079B1 (cs) * 1982-07-16 1984-09-17 Libuse Havlickova Způsob přípravy farmakologicky účinných derivátů 1,4-diaminoantrachinonu
JPS60199863A (ja) * 1984-03-23 1985-10-09 Dai Ichi Seiyaku Co Ltd アミノアンスラセン誘導体
EP0182135A3 (en) * 1984-11-19 1987-08-05 American Cyanamid Company Novel bis-(substituted amino) anthraquinones
GB8923075D0 (en) * 1989-10-13 1989-11-29 Patterson Laurence H Anti-cancer compounds
JPH07138212A (ja) * 1993-11-16 1995-05-30 Japan Tobacco Inc アミノアントラキノン化合物及びそれを含有してなる抗腫瘍剤
DE69909073T2 (de) * 1998-02-12 2004-05-19 De Montfort University Durch hydroxylierung aktivierte wirkstofffreigabe

Also Published As

Publication number Publication date
JP2002533418A (ja) 2002-10-08
DE69903974D1 (de) 2002-12-19
DK1140200T3 (da) 2003-03-10
AU1670100A (en) 2000-07-31
US6465522B1 (en) 2002-10-15
ATE227588T1 (de) 2002-11-15
ES2188273T3 (es) 2003-06-16
EP1140200A1 (en) 2001-10-10
CA2356399A1 (en) 2000-07-06
EP1140200B1 (en) 2002-11-13
GB9828670D0 (en) 1999-02-17
AU759549B2 (en) 2003-04-17
WO2000038734A1 (en) 2000-07-06
DE69903974T2 (de) 2003-09-04

Similar Documents

Publication Publication Date Title
FI903331A0 (fi) Substituerade kinazolinoner, vilka aer anvaendbara som angiotensin-ii-antagonister.
TR200102800T2 (tr) Yeni bileşikler.
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
AR006390A1 (es) Derivados de lactama
CO5210911A1 (es) Trifluorbutenos nematicidas
CY1107494T1 (el) Υποκατεστημενα παραγωγα πυριδυλμεθυλπιπepαζινης και πιπepιδινης, η παρασκευη τους και η χρηση τους για θepαπεια νοσων του κεντρικου νευρικου συστηματος (κνς)
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
BR0014199A (pt) Derivados de bifenila como inibidores de nhe-3
PT1140200E (pt) Medicamentos anticancerosos a base de antraquinona
ES2123873T3 (es) Pirrolocarbazol.
BR0213990A (pt) Derivados de piperazina tendo atividade antagonìstica de sst1
IL141830A0 (en) Chemiluminescent 1,2-dioxetane
BR0115996A (pt) Sulfamidotienopirimidinas
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
BR9902084A (pt) Heterociclos.
PE20000734A1 (es) Compuestos heterociclicos derivados de furopiridina y su uso terapeutico
BR0009453A (pt) Processo para a preparação de um composto
BR0108409A (pt) Derivados de aminoácidos e sua utilização como inibidores da nep, da ace e da ece
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
NZ510116A (en) Tricyclic delta-3-piperidines as pharmaceuticals
BR9912839A (pt) Derivados de piperazinomas e suas aplicações
DK0971907T3 (da) Fremgangsmåde til fremstilling af 1,3-disubstituerede 2-nitroguanidiner
ES2189162T3 (es) Colorantes disazoicos reactivos con las fibras.